A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients

References

• Nabeshima S, Kashiwagi K, Ajisaka K, et al. A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. J Infect Chemoth. 2012;18:534–543.
   PubMed Web of Science ®Google Scholar
• Kelly H, Birch C. The causes and diagnosis of influenza-like illness. Aust Fam Physician. 2004;33:305–309.
   PubMedGoogle Scholar
• National Institute of Infectious Diseases. IASR 36(11), Influenza 2014/15 season/Japan [Internet; cited 2016 Nov 7]. Available from: https://www.niid.go.jp/niid/en/iasr-e/865-iasr/6096-tpc429.html.
   Google Scholar
• Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States [Internet]. 2016 [updated 2016 Dec 13; cited 2017 Jan 18]. Available from: https://www.cdc.gov/flu/about/disease/2015-16.htm
   Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–5096.
   PubMed Web of Science ®Google Scholar
• National institute of infectious diseases. Influenza 2014/15 season, Japan [Internet]. 2015 [cited 2016 Nov 7]; Available from: http://www.nih.go.jp/niid/en/component/content/article/865-iasr/6096-tpc429.html
   Google Scholar
• Takaku F. Manual of therapeutic agents 2018. Igaku Syoin. 2018:1576–1581.
   Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363–1373.
   PubMed Web of Science ®Google Scholar
• Osaka JaFP, NJ – Shionogi & Co., Ltd. Shionogi to present S-033188 phase 3 CAPSTONE-1 study results for treatment of influenza at IDWEEK 2017 [Internet]. 2017 [cited 2018 Mar 7]; Available from: https://www.prnewswire.com/news-releases/shionogi-to-present-s-033188-phase-3-capstone-1-study-results-for-treatment-of-influenza-at-idweek-2017-300531077.html
   Google Scholar
• Portsmouth S, Kawaguchi K, Arai M, et al. Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza. Open Forum Infectious Dis. 2017;4:S734.
   Google Scholar
• Centre for Reviews and Dissemination, U.o.Y. Systematic Reviews – CRD’s guidance for undertaking reviews in health care. York: University of York; 2008.
   Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [Internet]. 2011 [cited 2016 Nov 7]; Available from: http://handbook-5-1.cochrane.org/
   Google Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313–2324.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. People at High Risk of Developing Flu-Related Complications [Internet] [cited 2017 March 6]. Available from: https://www.cdc.gov/flu/about/disease/high_risk.htm
   Google Scholar
• Spiegelhalter D, Best N, Carlin B, et al. Bayesian measures of model complexity and fit. Quality Control Appl Statistics. 2003;48:431–432.
   Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–617.
   PubMed Web of Science ®Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568–4574.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–1024.
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845–1850.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antivir Ther. 1999;4:61–68.
   PubMed Web of Science ®Google Scholar
• Li L, Cai B, Wang M, et al. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J (Engl). 2003;116:44–48.
   PubMed Web of Science ®Google Scholar
• Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis. 2003;35:52–58.
   PubMed Web of Science ®Google Scholar
• Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267–5276.
   PubMed Web of Science ®Google Scholar
• Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir–zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167–1175.
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Hardy I, et al. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis. 2000;181:1471–1474.
   PubMed Web of Science ®Google Scholar
• Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40:42–48.
   PubMed Web of Science ®Google Scholar
• Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254–261.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874–880.
   PubMed Web of Science ®Google Scholar
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. PubMed PMID. 1998;352:1877–1881.
   PubMed Web of Science ®Google Scholar
• Management of Influenza in the Southern Hemisphere Trialists (MIST). BioCryst Pharmaceuticals. Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza [Internet]. 2007 [cited 2016 Nov 25]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00419263?term=NCT00419263&rank=1
   Google Scholar
• Ikematsu. Clinical efficacy at the early stage of inhaled anti-influenza drug zanamivir after inhalation randomized open label test. J Japan Clin Inter Med Assoc. 2011;26(2):215–219.
   Google Scholar
• Kashiwagi S, Kudoh S, Watanabe A, et al. [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza – placebo-controlled double-blind multicenter phase III trial]. kansenshogakuzasshi. 2000;74:1044–1061.
   PubMedGoogle Scholar
• Pharmaceuticals and Medical Devices Agency. Relenza (Zanamivir) package insert. 2017.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Report on the Deliberation Results (Laninamivir). 2010.
   Google Scholar
• Food and Drug Administration. Center for drug evaluation and research (Application number: 021246Orig1s045 and 021087Orig1s062) Labeling. 2012.
   Google Scholar
• Suess T, Remschmidt C, Schink SB, et al. Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007–2011. PLoS One. 2012;7:e51653.
   PubMed Web of Science ®Google Scholar
• Lau LL, Ip DK, Nishiura H, et al. Heterogeneity in viral shedding among individuals with medically attended influenza A virus infection. J Infect Dis. 2013;207:1281–1285.
   PubMed Web of Science ®Google Scholar
• Fielding JE, Kelly HA, Mercer GN, et al. Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Resp. 2014;8:142–150.
   PubMed Web of Science ®Google Scholar
• Tsang TK, Cowling BJ, Fang VJ, et al. Influenza A virus shedding and infectivity in households. J Infect Dis. 2015;212:1420.
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Novikov DV, Hayden FG. Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families. J Infect Dis. 2002;186:1575.
   PubMed Web of Science ®Google Scholar
• Poon LL, Chan KH, Chu DK, et al. Viral genetic sequence variations in pandemic H1N1/2009 and seasonal H3N2 influenza viruses within an individual, a household and a community. J Clin Virol. 2011;52:146–150.
   PubMed Web of Science ®Google Scholar
• Papenburg J, Baz M, Hamelin ME, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis. 2010;51:1033. America.
   PubMed Web of Science ®Google Scholar
• Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;18:CD002744.
   Google Scholar
• Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–265, iii–iv.
   PubMed Web of Science ®Google Scholar
• Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7:iii–iv, xi–xiii, 1–170.
   PubMedGoogle Scholar
• Gums JG, Pelletier Em, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9:151–161.
   Google Scholar
• Chow MY, Morrow AM, Booy R, et al. Impact of children’s influenza-like illnesses on parental quality of life: a qualitative study. J Paediatr Child Health. 2013;49(8):664–670.
   Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965.
   PubMed Web of Science ®Google Scholar
• To MJ, Jones J, Emara M, et al. Are reports of randomized controlled trials improving over time? A systematic review of 284 articles published in high-impact general and specialized medical journals. PLoS One. 2013;8:e84779.
   PubMed Web of Science ®Google Scholar